These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 19081511

  • 1. New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab.
    Hartung HP.
    Lancet Neurol; 2009 Jan; 8(1):28-31. PubMed ID: 19081511
    [No Abstract] [Full Text] [Related]

  • 2. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.
    Bartt RE.
    Curr Opin Neurol; 2006 Aug; 19(4):341-9. PubMed ID: 16914971
    [Abstract] [Full Text] [Related]

  • 3. Natalizumab for multiple sclerosis: a complicated treatment.
    Keegan BM.
    Lancet Neurol; 2011 Aug; 10(8):677-8. PubMed ID: 21777819
    [No Abstract] [Full Text] [Related]

  • 4. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis.
    Kleinschmidt-DeMasters BK, Tyler KL.
    N Engl J Med; 2005 Jul 28; 353(4):369-74. PubMed ID: 15947079
    [Abstract] [Full Text] [Related]

  • 5. Progressive multifocal leukoencephalopathy, natalizumab, and multiple sclerosis.
    Alvarez-Cermeño JC, Masjuan J, Villar LM.
    N Engl J Med; 2005 Oct 20; 353(16):1744-6; author reply 1744-6. PubMed ID: 16240475
    [No Abstract] [Full Text] [Related]

  • 6. Natalizumab (Tysabri) returns.
    Med Lett Drugs Ther; 2006 Sep 11; 48(1243):76. PubMed ID: 16977289
    [No Abstract] [Full Text] [Related]

  • 7. Successful management of natalizumab-associated progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient with multiple sclerosis.
    Schröder A, Lee DH, Hellwig K, Lukas C, Linker RA, Gold R.
    Arch Neurol; 2010 Nov 11; 67(11):1391-4. PubMed ID: 20625069
    [Abstract] [Full Text] [Related]

  • 8. Natalizumab for relapsing multiple sclerosis.
    Tenser RB.
    N Engl J Med; 2006 Jun 01; 354(22):2387-9; author reply 2387-9. PubMed ID: 16738278
    [No Abstract] [Full Text] [Related]

  • 9. Quantitative risk-benefit analysis of natalizumab.
    Steiner I.
    Neurology; 2009 May 19; 72(20):1791-2; author reply 1791-2. PubMed ID: 19451538
    [No Abstract] [Full Text] [Related]

  • 10. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
    Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, Lublin FD, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, Sandrock AW, SENTINEL Investigators.
    N Engl J Med; 2006 Mar 02; 354(9):911-23. PubMed ID: 16510745
    [Abstract] [Full Text] [Related]

  • 11. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab.
    Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D.
    N Engl J Med; 2005 Jul 28; 353(4):375-81. PubMed ID: 15947078
    [Abstract] [Full Text] [Related]

  • 12. Natalizumab for relapsing multiple sclerosis.
    Jeffery DR.
    N Engl J Med; 2006 Jun 01; 354(22):2387-9; author reply 2387-9. PubMed ID: 16742008
    [No Abstract] [Full Text] [Related]

  • 13. Selective treatment of multiple sclerosis.
    Ropper AH.
    N Engl J Med; 2006 Mar 02; 354(9):965-7. PubMed ID: 16510751
    [No Abstract] [Full Text] [Related]

  • 14. Clinical and paraclinical findings in natalizumab-associated infratentorial progressive multifocal leukoencephalopathy patients.
    Hoepner R, Ahlbrecht J, Faissner S, Schneider R, Dahlhaus S, Adams O, Raab P, Lukas C, Chan A, Stangel M, Gold R.
    J Neurol Neurosurg Psychiatry; 2014 Oct 02; 85(10):1177-8. PubMed ID: 24700881
    [No Abstract] [Full Text] [Related]

  • 15. Clinically silent PML and prolonged immune reconstitution inflammatory syndrome in a patient with multiple sclerosis treated with natalizumab.
    Blinkenberg M, Sellebjerg F, Leffers AM, Madsen CG, Sørensen PS.
    Mult Scler; 2013 Aug 02; 19(9):1226-9. PubMed ID: 23508652
    [Abstract] [Full Text] [Related]

  • 16. Fingolimod to treat severe multiple sclerosis after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?
    Maillart E, Louapre C, Lubetzki C, Papeix C.
    Mult Scler; 2014 Apr 02; 20(4):505-9. PubMed ID: 24367037
    [Abstract] [Full Text] [Related]

  • 17. Transient punctuate enhancing lesions preceding natalizumab-associated progressive multifocal leukoencephalopathy.
    Taieb G, Renard D, Thouvenot E, Servillo G, Castelnovo G.
    J Neurol Sci; 2014 Nov 15; 346(1-2):364-5. PubMed ID: 25241939
    [No Abstract] [Full Text] [Related]

  • 18. [Progressive multifocal leukoencephalopathy as a complication of natalizumab therapy].
    Soilu-Hänninen M, Päivärinta M, Sonninen P, Parkkola R, Vuorinen T, Erälinna JP.
    Duodecim; 2013 Nov 15; 129(7):765-70. PubMed ID: 23720945
    [Abstract] [Full Text] [Related]

  • 19. JCV-negative natalizumab-associated progressive multifocal leukoencephalopathy: a clinico-radiological diagnosis.
    Travasarou M, Marousi S, Papageorgiou E, Karageorgiou CE.
    Clin Neurol Neurosurg; 2013 Jun 15; 115(6):827-9. PubMed ID: 22920632
    [No Abstract] [Full Text] [Related]

  • 20. Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis.
    Zivadinov R, Dwyer MG, Hussein S, Carl E, Kennedy C, Andrews M, Hojnacki D, Heininen-Brown M, Willis L, Cherneva M, Bergsland N, Weinstock-Guttman B.
    Mult Scler; 2012 Aug 15; 18(8):1125-34. PubMed ID: 22194217
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.